دورية أكاديمية
أعرض في EDS

Establishment of a murine model of breast cancer expressing human epidermal growth factor receptor 2 (4T1-HER2).

التفاصيل البيبلوغرافية
العنوان: Establishment of a murine model of breast cancer expressing human epidermal growth factor receptor 2 (4T1-HER2).
المؤلفون: Bakhtiarvand VK; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Akbari KR; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Sadri F; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran., Haghighat FN; Monoclonal Antibody Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran., Hojjat-Farsangi M; Department of Oncology-Pathology, BioClinicum Karolinska University Hospital Solna and Karolinska Institute, 17164 Stockholm, Sweden., Shokri F; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran., Jeddi-Tehrani M; Monoclonal Antibody Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran., Shabani M; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
المصدر: Journal of cancer research and therapeutics [J Cancer Res Ther] 2024 Apr 01; Vol. 20 (3), pp. 984-992. Date of Electronic Publication: 2023 Apr 04.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-4138 (Electronic) Linking ISSN: 19984138 NLM ISO Abbreviation: J Cancer Res Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Mumbai, India : Medknow Publications
مواضيع طبية MeSH: Breast Neoplasms*/pathology , Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism , Breast Neoplasms*/therapy , Disease Models, Animal* , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics, Animals ; Female ; Humans ; Mice ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Cell Line, Tumor ; Cell Proliferation ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Xenograft Model Antitumor Assays
مستخلص: Aim: Although people with HER2-positive breast cancer benefit from approved HER2-targeted therapy, acquiring resistance to the therapies occurs. Animal models can play a part in gaining a deep understanding of such a process and addressing questions concerning developing and improving immunotherapy approaches.
Materials and Methods: To develop such a model, we transfected murine 4T1 cells with the pCMV6-Neo-HER2 construct and evaluated HER2 expression and its effects on the established cell line behavior in vitro and in vivo.
Results: Data illustrated that human HER2 protein was expressed on isolated 4T1-HER2 clones in vitro and in vivo. Except for proliferation over 48 hours, such expression did not change 4T1-HER2 characteristics compared to 4T1 in vitro. Notwithstanding the reduction in proliferation, the rate of tumorigenicity was 90% in challenged mice and Herceptin therapy significantly decreased tumors' growth and metastasis compared to the control group.
Conclusion: We describe a murine model for HER2-positive breast cancer not only helping shed light on the mechanisms by which the tumor evades antitumor immunity but also playing a key role in making breast cancer more sensitive to novel immunotherapy modalities.
(Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics.)
References: Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209–49.
Al-Thoubaity FK. Molecular classification of breast cancer:A retrospective cohort study. AnnMed Surg (Lond) 2020;49:44–8.
Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in cancers:Overexpression and therapeutic implications. Mol Biol Int 2014;2014:852748.
Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in HER2-targeted therapy:Novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res 2019;25:2033–41.
Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, et al. Sequential anti-PD1 therapy following dendritic cell vaccination improves survival in a HER2 mammary carcinoma model and identifies a critical role for CD4 T cells in mediating the response. Front Immunol 2019;10:1939.
Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, et al. If we build it they will come:Targeting the immune response to breast cancer. NPJ Breast Cancer 2019;5:37.
Holen I, Speirs V, Morrissey B, Blyth K. In vivo models in breast cancer research:Progress, challenges and future directions. Dis Model Mech 2017;10:359–71.
Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133–42.
Roy LD, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P. Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast CancerRes 2009;11:56.
Whittington PJ, Radkevich-Brown O, Jacob JB, Jones RF, Weise AM, Wei WZ. Her-2 DNA versus cell vaccine:Immunogenicity and anti-tumor activity. Cancer Immunol Immunother 2009;58:759–67.
Park S, Nedrow JR, Josefsson A, Sgouros G. Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV. f. HuHER2 mice:Characterization and use in a model of metastatic breast cancer. Oncotarget 2017;8:68071–82.
Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 2004;173:2143–50.
Sakamoto K, Schmidt JW, Wagner K-U. Mouse Models of Breast Cancer. Mouse Models ofCancer: Springer; 2015:47–71.
Amiri MM, Jeddi-Tehrani M, Kazemi T, Bahadori M, Maddah M, Hojjat-Farsangi M, et al. Construction and characterization of a new chimeric antibody against HER2. Immunotherapy 2013;5:703–15.
Galon J, Bruni D. Tumor immunology and tumor evolution:Intertwined histories. Immunity 2020;52:55–81.
Zigler M, Shir A, Levitzki A. Targeted cancer immunotherapy. Curr Opin Pharmacol 2013;13:504–10.
Arab A, Yazdian-Robati R, Behravan J. HER2-positive breast cancer immunotherapy:A focus on vaccine development. Arch Immunol Ther Exp (Warsz) 2020;68:2.
Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004;16:143–50.
Vernon AE, Bakewell SJ, Chodosh LA. Deciphering the molecular basis of breast cancer metastasis with mouse models. Rev Endocr Metab Disord 2007;8:199–213.
Siegler EL, Wang P. Preclinical models in chimeric antigen receptor–engineered T-cell therapy. Hum Gene Ther 2018;29:534–46.
Sharpless NE, Depinho RA. The mighty mouse:Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741–54.
Manning HC, Buck JR, Cook RS. Mouse models of breast cancer:Platforms for discovering precision imaging diagnostics and future cancer medicine. J Nucl Med 2016;57 (Suppl 1):60S–8S.
DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514–20.
DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, et al. Patient-derived models of human breast cancer:Protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol 2013. doi:10.1002/0471141755.ph 1423s60. (PMID: 10.1002/0471141755.ph)
Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007;2:247–50.
Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645–58.
Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr ProtocImmunol 2001. doi:10.1002/0471142735.im2002s39. (PMID: 10.1002/0471142735.im2002s39)
Kim IS, Baek SH. Mouse models for breast cancer metastasis. Biochem Biophys Res Commun 2010;394:443–7.
Rivera A, Fu X, Tao L, Zhang X. Modification of a popular syngeneic murine mammary tumor model for immunotherapy studies. Int Sch Res Notices 2011;2011.
Piechocki MP, Pilon SA, Kelly C, Wei WZ. Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine–alanine repeat. Cell Immunol 2001;212:138–49.
Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 1999;49:179–88.
Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399–405.
Han BS, Ji S, Woo S, Lee JH, Sin JI. Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model. Sci Rep 2019;9:2855.
Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479–91.
Lowenfeld L, Xu S, Czerniecki BJ. CD4+Th1 to the rescue in HER-2+breast cancer. Oncoimmunology 2018;8:e1078062.
Nilofar Danishmalik S, Lee SH, Sin JI. Tumor regression is mediated via the induction of HER263-71-specific CD8+CTL activity in a 4T1. 2/HER2 tumor model:No involvement of CD80 in tumor control. Oncotarget 2017;8:26771–88.
Danishmalik SN, Sin JI. Therapeutic tumor control of HER2 DNA vaccines is achieved by an alteration of tumor cells and tumor microenvironment by gemcitabine and anti-Gr-1 Ab treatment in a HER2-expressing tumor model. DNA Cell Biol 2017;36:801–11.
المشرفين على المادة: 0 (Antineoplastic Agents, Immunological)
EC 2.7.10.1 (ERBB2 protein, human)
EC 2.7.10.1 (Receptor, ErbB-2)
P188ANX8CK (Trastuzumab)
تواريخ الأحداث: Date Created: 20240718 Date Completed: 20240718 Latest Revision: 20240805
رمز التحديث: 20240805
DOI: 10.4103/jcrt.jcrt_1303_22
PMID: 39023607
قاعدة البيانات: MEDLINE
الوصف
تدمد:1998-4138
DOI:10.4103/jcrt.jcrt_1303_22